Overview
IGF-1 LR3 is a modified version of insulin-like growth factor 1 — the hormone through which most of growth hormone anabolic effects are actually executed. The LR3 modification (a 13-amino-acid extension plus an arginine substitution) prevents binding to IGF binding proteins, extending its half-life from minutes to 20-30 hours and dramatically increasing potency.
It is one of the most powerful anabolic agents in the grey-market arsenal — and one of the most dangerous.
How It Works
IGF-1 is the primary mediator of growth hormone action on muscle. It activates the IGF-1 receptor, triggering the PI3K/Akt/mTOR pathway — the central anabolic signaling cascade — and promoting both muscle protein synthesis and satellite cell proliferation.
Hyperplasia vs hypertrophy
Unlike most anabolics that enlarge existing muscle fibers, IGF-1 can theoretically increase fiber number by activating satellite cells — the reason bodybuilders are fascinated by it, and the reason its effects may be more permanent than other compounds.
Key Benefits
Potent anabolism — direct activation of the main muscle-building pathway.
Nutrient partitioning — shuttles glucose and amino acids into muscle.
Recovery — accelerated repair of muscle damage.
Fat loss — improved insulin sensitivity in muscle (though systemic effects differ).
Side Effects & Considerations
This is where IGF-1 LR3 demands respect. Hypoglycemia is a real and immediate risk — IGF-1 lowers blood sugar like insulin, and dosing errors can be dangerous. Organ growth (intestinal, cardiac) is documented with chronic GH/IGF-1 elevation.
The cancer issue is not theoretical here
IGF-1 is a growth factor for every cell that has its receptor — including tumors. Epidemiological links between high IGF-1 and several cancers are well established. Using a long-acting, super-potent IGF-1 analogue is arguably the highest-risk practice in the peptide world. WADA prohibited, not approved for human use, and unforgiving of mistakes.
Dosage protocols
| Protocol | Dosage | Frequency | Duration | Notes |
|---|---|---|---|---|
| Community protocol (anecdotal) | 20-50 mcg | Once daily, post-workout | 4-6 weeks maximum | Bilateral injection into trained muscles is common practice. Hypoglycemia risk requires carbohydrates on hand. |
Warnings
High-risk compound: hypoglycemia, organ growth, and serious cancer-growth concerns. Not approved for human use. WADA prohibited.